Preview: GSK won't bounce back in Q2
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is likely to post another set of weak quarterly figures later this week. Following a first quarter hit by sluggish respiratory sales and the continuing backlash in China following bribery allegations, neither situation has improved in the next three months.